Jun 2026 (Q2 FY26) — Aug 6, 2026
Amylyx Pharmaceuticals Q2 FY26 — Avexitide Phase 3 LUCIDITY Data Readout Imminent
Read the full callAmylyx Pharmaceuticals (AMLX) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Amylyx Pharmaceuticals earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | Quarterly, as filed | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Operating margin | Operating profit / revenue | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Net profit | -43.4 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$27.33 +3.76% · +$0.99
Performance +82.8% 1Y
1Y: $14.95 on 17 Oct 2025 → $27.33. High $39.66 (20 Aug 2026), low $11.38 (6 Jan 2026).
- Previous close
- $26.34
- 52-week range
- $11.38 – $39.66
- One year
- +77.81%
Overview
- Symbol
- AMLX
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Amylyx Pharmaceuticals earnings calls (AMLX)
Financials
What the filings say
Net profit, year on year: −5% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0 | — | 0 | 0 | 0 | 0 | — | — |
| Expenses | 76 | 40 | 38 | 43 | 36 | 37 | 44 | 46 |
| Operating profit | -76 | -41 | -38 | -43 | -36 | -37 | -44 | -46 |
| Operating margin | −18187.7% | — | — | — | — | — | — | — |
| Other income | 3 | 2 | 2 | 1 | 2 | 4 | 2 | 2 |
| Profit before tax | -73 | -38 | -36 | -41 | -34 | -33 | — | — |
| Tax rate | 0.0% | 1.7% | 0.0% | 0.0% | 0.0% | −0.1% | — | — |
| Net profit | -73 | -38 | -36 | -41 | -34 | -33 | -41 | -43 |
| EPS ($ per share) | -1.07 | — | -0.42 | -0.46 | -0.37 | — | -0.37 | -0.39 |
| Line item | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 |
| Reserves | -156 | -354 | -305 | -607 | -751 |
| Total liabilities | 17 | 51 | 84 | 29 | 27 |
| Fixed assets | 0 | 3 | 3 | 1 | 0 |
| Investments | 46 | 284 | 201 | 99 | 90 |
| Total assets | 106 | 391 | 517 | 194 | 333 |
| Line item | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Cash from operations | -75 | -180 | 12 | -168 | -123 |
| Cash from investing | -46 | -239 | 92 | 76 | 14 |
| Cash from financing | 159 | 432 | 4 | 0 | 257 |
| Net cash flow | 37 | 13 | 108 | -92 | 149 |
| Capital expenditure | -0 | -3 | -1 | -0 | -0 |
| Free cash flow | -75 | -182 | 11 | -168 | -123 |
Insider filings
50 filings between Dec 1, 2025 and Oct 5, 2026.
Open market
decisions to buy or sellPurchases
$152.2K
2 purchases by 1 insider
Sales
$10.14M
31 sales by 6 insiders
10% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 10
- Award — granted as compensation
- 6
- Option exercise — converted options into shares
Also filed: 1 gift.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Cohen Joshua B | — | $3.60M | Sep 10, 2026 |
| Klee Justin B. | — | $3.59M | Sep 10, 2026 |
| Mazzariello Gina | — | $1.05M | Sep 10, 2026 |
| MILNE GEORGE M JR | — | $830.9K | Oct 5, 2026 |
| FRATES JAMES M | — | $553.7K | Sep 10, 2026 |
| Bedrosian Camille L | — | $513.5K | Sep 10, 2026 |
| Firestone Karen | $152.2K | — | May 21, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 5, 2026 | MILNE GEORGE M JR Director | Sale 10b5-1 plan | 30,000 | $830.9K |
| Sep 10, 2026 | Klee Justin B. Co-Chief Executive Officer | Sale | 1,439 | $47.7K |
| Sep 10, 2026 | Klee Justin B. Co-Chief Executive Officer | Sale | 29,025 | $932.6K |
| Sep 10, 2026 | Cohen Joshua B Co-Chief Executive Officer | Sale | 29,545 | $950.0K |
| Sep 10, 2026 | Bedrosian Camille L Chief Medical Officer | Sale | 2,081 | $68.9K |
| Sep 10, 2026 | Bedrosian Camille L Chief Medical Officer | Sale | 7,947 | $256.0K |
| Sep 10, 2026 | FRATES JAMES M Chief Financial Officer | Sale | 1,042 | $34.6K |
| Sep 10, 2026 | FRATES JAMES M Chief Financial Officer | Sale | 9,768 | $315.2K |
| Sep 10, 2026 | Mazzariello Gina Chief Legal Officer | Sale | 11 | $367 |
| Sep 10, 2026 | Mazzariello Gina Chief Legal Officer | Sale | 9,525 | $309.1K |
| Sep 10, 2026 | Cohen Joshua B Co-Chief Executive Officer | Sale | 919 | $30.5K |
| Aug 31, 2026 | Firestone Karen Director | Option exercise | 25,000 | $126.3K |
| Aug 31, 2026 | Firestone Karen Director | Option exercise | 25,000 | $44.0K |
| Aug 18, 2026 | Cohen Joshua B Co-Chief Executive Officer | Award | 60,039 | $0 |
| Aug 18, 2026 | FRATES JAMES M Chief Financial Officer | Award | 22,807 | $0 |
| Aug 18, 2026 | Bedrosian Camille L Chief Medical Officer | Award | 22,807 | $0 |
| Aug 18, 2026 | Mazzariello Gina Chief Legal Officer | Award | 21,284 | $0 |
| Aug 18, 2026 | Klee Justin B. Co-Chief Executive Officer | Award | 60,039 | $0 |
| Jul 10, 2026 | Mazzariello Gina Chief Legal Officer | Sale 10b5-1 plan | 15,000 | $264.1K |
| Jul 9, 2026 | Mazzariello Gina Chief Legal Officer | Sale 10b5-1 plan | 15,000 | $274.7K |
| May 21, 2026 | Firestone Karen Director | Purchase | 3,800 | $51.3K |
| Mar 5, 2026 | Mazzariello Gina Chief Legal Officer | Award | 74,660 | $0 |
| Mar 5, 2026 | Bedrosian Camille L Chief Medical Officer | Award | 95,990 | $0 |
| Mar 5, 2026 | Klee Justin B. Co-Chief Executive Officer | Award | 248,865 | $0 |
| Mar 5, 2026 | FRATES JAMES M Chief Financial Officer | Award | 95,990 | $0 |
| Mar 5, 2026 | Cohen Joshua B Co-Chief Executive Officer | Award | 248,865 | $0 |
| Mar 2, 2026 | Mazzariello Gina Chief Legal Officer | Sale | 6,844 | $99.4K |
| Mar 2, 2026 | Klee Justin B. Co-Chief Executive Officer | Sale | 29,282 | $423.8K |
| Mar 2, 2026 | Cohen Joshua B Co-Chief Executive Officer | Sale | 29,282 | $424.1K |
| Mar 2, 2026 | Bedrosian Camille L Chief Medical Officer | Sale | 6,461 | $94.2K |
| Mar 2, 2026 | FRATES JAMES M Chief Financial Officer | Sale | 7,909 | $114.9K |
| Feb 23, 2026 | Mazzariello Gina Chief Legal Officer | Sale | 3,419 | $48.4K |
| Feb 2, 2026 | FRATES JAMES M Chief Financial Officer | Sale | 3,557 | $52.1K |
| Feb 2, 2026 | Klee Justin B. Co-Chief Executive Officer | Sale | 15,500 | $227.6K |
| Feb 2, 2026 | Mazzariello Gina Chief Legal Officer | Sale | 3,448 | $50.5K |
| Feb 2, 2026 | Cohen Joshua B Co-Chief Executive Officer | Sale | 15,500 | $227.6K |
| Jan 16, 2026 | Cohen Joshua B Co-Chief Executive Officer | Option exercise | 2,818 | $21.3K |
| Jan 16, 2026 | Klee Justin B. Co-Chief Executive Officer | Option exercise | 2,847 | $21.6K |
| Jan 16, 2026 | Cohen Joshua B Co-Chief Executive Officer | Sale | 1,974 | $27.3K |
| Jan 16, 2026 | Klee Justin B. Co-Chief Executive Officer | Sale | 1,995 | $27.7K |
| Jan 15, 2026 | Cohen Joshua B Co-Chief Executive Officer | Option exercise | 197,182 | $1.49M |
| Jan 15, 2026 | Klee Justin B. Co-Chief Executive Officer | Sale | 136,193 | $1.85M |
| Jan 15, 2026 | Klee Justin B. Co-Chief Executive Officer | Option exercise | 197,153 | $1.49M |
| Jan 15, 2026 | Cohen Joshua B Co-Chief Executive Officer | Sale | 136,193 | $1.85M |
| Jan 12, 2026 | MILNE GEORGE M JR Director | Gift | 17,780 | $0 |
| Jan 6, 2026 | FRATES JAMES M Chief Financial Officer | Sale | 3,326 | $37.0K |
| Jan 6, 2026 | Klee Justin B. Co-Chief Executive Officer | Sale | 7,715 | $85.6K |
| Jan 6, 2026 | Cohen Joshua B Co-Chief Executive Officer | Sale | 7,715 | $85.6K |
| Dec 23, 2025 | Firestone Karen Director | Purchase | 8,100 | $100.8K |
| Dec 1, 2025 | Bedrosian Camille L Chief Medical Officer | Sale | 6,580 | $94.4K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Amylyx Pharmaceuticals, Inc.
Free account. Everything above stays public.
Write why you follow Amylyx Pharmaceuticals, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading